mortality in the current era: a CIBMTR analysis. Blood. 2016; 127(20):2427–2438.13 13. Radivoyevitch T, Dean RM, Shaw BE, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018; 74:130–136.
14 14. Gabriel M, Shaw BE, Brazauskas R, et al. Risk factors for subsequent central nervous system tumors in pediatric allogeneic hematopoietic cell transplant: a study from the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2017; 23(8):1320–1326.
15 15. Shaw BE, Hahn T, Martin PJ, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. Biol Blood Marrow Transplant. 2017; 23(1):10–23.
16 16. Chow EJ, Anderson L, Baker KS, et al. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biol Blood Marrow Transplant. 2016; 22(5):782–795.
17 17. Gebauer J, Rieken S, Schuster S, et al. Multidisciplinary Late Effects Clinics for Childhood Cancer Survivors in Germany: A Two‐Center Study. Oncol Res Treat. 2018; 41(7–8):430–436.
18 18. Signorelli C, Wakefield CE, McLoone JK, et al. Models of childhood cancer survivorship care in Australia and New Zealand: Strengths and challenges. Asia Pac J Clin Oncol. 2017; 13(6):407–415.
19 19. Signorelli C, Wakefield CE, Fardell JE, et al. The impact of long‐term follow‐up care for childhood cancer survivors: A systematic review. Crit Rev Oncol Hematol. 2017; 114:131–138.
20 20. Nathan PC, Agha M, Pole JD, et al. Predictors of attendance at specialized survivor clinics in a population‐based cohort of adult survivors of childhood cancer. J Cancer Surviv. 2016; 10(4):611–618.
21 21. Groarke JM, Richmond J, Kelly MG, et al. Examining the Impact of a Personalized Self‐Management Lifestyle Program Using Mobile Technology on the Health and Well‐Being of Cancer Survivors: Protocol and Rationale for a Randomized Controlled Trial (The Moving On Study). JMIR Res Protoc. 2019; 8(8):e13214.
22 22. O'Malley DM, Davis SN, Devine KA, et al. Development and usability testing of the e‐EXCELS tool to guide cancer survivorship follow‐up care. Psychooncology. 2019; 29(1):123–131.
23 23. Quintiliani LM, Foster M, Oshry LJ. Preferences of mHealth app features for weight management among breast cancer survivors from underserved populations. Psychooncology. 2019; 28(10):2101–2104.
24 24. Zinter MS, Logan BR, Fretham C, et al. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biol Blood Marrow Transplant. 2020; 26(2):333–342.
25 25. Herr MM, Curtis RE, Tucker MA, et al. Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. J Am Acad Dermatol. 2019;S1090–9622( 19):32952–32954.
26 26. Duncan CN, Brazauskas R, Huang J, et al. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2018; 53(10):1278–1287.
27 27. Vrooman LM, Millard HR, Brazauskas R, et al. Survival and late effects after allogeneic hematopoietic cell transplantation for hematologic malignancy at less than three years of age. Biol Blood Marrow Transplant. 2017; 23(8):1327–1334.
28 28. Bhatt NS, Brazauskas R, Tecca HR, et al. Female sex is associated with poor health‐related quality of life in children at 12 months post‐hematopoietic cell transplantation. J Pediatr Hematol Oncol. 2019; 41(3):233–237.
29 29. D'Souza A, Millard H, Knight J, et al. Prevalence of self‐reported sleep dysfunction before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2018; 53(8):1079–1082.
30 30. Norkin M, Shaw BE, Brazauskas R, et al. Characteristics of late fatal infections after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(2):362–368.
31 31. Myers RM, Hill BT, Shaw BE, et al. Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma. Cancer. 2018; 124(4):816–825.
32 32. Gratwohl A, Brand R, McGrath E, et al. Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Haematologica. 2014; 99(5):908–915.
33 33. Schetelig J, Wreede LC, Andersen NS, et al. Center characteristics and procedure‐related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: A retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2017; 178(4):521–533.
34 34. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11–18.
35 35. Passweg JR, Baldomero H, Chabannon C, et al. The EBMT activity survey on hematopoietic‐cell transplantation and cellular therapy 2018: CAR‐T's come into focus. Bone Marrow Transplant. 2020; 55(8):1604–1613.
36 36. Snowden JA, Saccardi R, Orchard K, et al. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: a review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2020; 55(4):681–694.
37 37. Cesaro S, Pillon M, Sauer M, et al. Long‐term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman‐Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP‐EBMT). Bone Marrow Transplant. 2020; doi: 10.1038/s41409‐020‐0863‐z. [Online ahead of print].
38 38. Giardino S, de Latour RP, Aljurf M, et al. Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: a retrospective analysis on behalf of EBMT group. Am J Hematol. 202095(7):809–816.
39 39. Penack O, Peczynski C, van der Werf S, et al. Association of serum ferritin levels before start of conditioning with mortality after alloSCT: A Prospective, Non‐interventional Study of the EBMT Transplant Complications Working Party. Front Immunol. 2020; 11:586.
40 40. Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem‐cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020; 7(2):e157–e167.
41 41. Iida M, Kodera Y, Dodds A, et al. Advances in hematopoietic stem cell transplantation in the Asia‐Pacific region: the second report from APBMT 2005‐2015. Bone Marrow Transplant. 2019; 54(12):1973–1986.
42 42. Nations U. World Population Prospects 2019. 2019.
43 43. Yoshimi A, Suzuki R, Atsuta Y, et al. Hematopoietic SCT activity in Asia: a report from the Asia‐Pacific Blood and Marrow Transplantation Group. Bone Marrow Transplant. 2010; 45(12):1682–1691.
44 44. Ashton LJ, Le Marsney RE, Dodds AJ, et al.
